Literature DB >> 25531207

Activation of checkpoint kinase 2 is critical for herpes simplex virus type 1 replication in corneal epithelium.

Oleg Alekseev1, Vladimir Limonnik, Kelly Donovan, Jane Azizkhan-Clifford.   

Abstract

BACKGROUND/AIMS: Herpes simplex virus (HSV) type I keratitis remains a leading cause of corneal morbidity, despite the availability of effective antiviral drugs. Improved understanding of virus-host interactions at the level of the host DNA damage response (DDR), a known factor in the development of HSV-1 keratitis, may shed light on potential new therapeutic targets. This report examines the role of checkpoint kinase 2 (Chk2), a DDR mediator protein, in corneal epithelial HSV-1 infection.
METHODS: A small-molecule inhibitor of Chk2 (Chk2 inhibitor II) was applied to HSV-1-infected cultured human corneal epithelial cells (hTCEpi and HCE) as well as to explanted and organotypically cultured human and rabbit corneas. Infection levels were assessed by plaque assay and real-time PCR. RNAi-mediated depletion of Chk2 was performed to confirm the effect of the inhibitor.
RESULTS: Inhibition of the Chk2 kinase activity greatly suppresses the cytopathic effect, genome replication and infectious progeny production in vitro and ex vivo.
CONCLUSION: This report demonstrates the critical role of Chk2 kinase in the establishment of HSV-1 corneal epithelial infection. These data contribute to our understanding of herpesvirus-host interactions and underscore the significance of DDR activation in HSV-1 keratitis.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25531207      PMCID: PMC4380435          DOI: 10.1159/000366228

Source DB:  PubMed          Journal:  Ophthalmic Res        ISSN: 0030-3747            Impact factor:   2.892


  55 in total

1.  Chk2-deficient mice exhibit radioresistance and defective p53-mediated transcription.

Authors:  Hiroyuki Takai; Kazuhito Naka; Yuki Okada; Miho Watanabe; Naoki Harada; Shin'ichi Saito; Carl W Anderson; Ettore Appella; Makoto Nakanishi; Hiroshi Suzuki; Kazuo Nagashima; Hirofumi Sawa; Kyoji Ikeda; Noboru Motoyama
Journal:  EMBO J       Date:  2002-10-01       Impact factor: 11.598

Review 2.  The ATM protein kinase: regulating the cellular response to genotoxic stress, and more.

Authors:  Yosef Shiloh; Yael Ziv
Journal:  Nat Rev Mol Cell Biol       Date:  2013-03-13       Impact factor: 94.444

3.  A retrospective, case-control study of acyclovir resistance in herpes simplex virus.

Authors:  Denis Malvy; Michèle Treilhaud; Stéphane Bouée; Anne Crochard; Denis Vallée; Abdelkader El Hasnaoui; Michele Aymard
Journal:  Clin Infect Dis       Date:  2005-06-14       Impact factor: 9.079

Review 4.  CHK2 kinase--a busy messenger.

Authors:  J Bartek; J Falck; J Lukas
Journal:  Nat Rev Mol Cell Biol       Date:  2001-12       Impact factor: 94.444

5.  The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis.

Authors:  J Falck; N Mailand; R G Syljuåsen; J Bartek; J Lukas
Journal:  Nature       Date:  2001-04-12       Impact factor: 49.962

6.  Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo and in vitro.

Authors:  S Matsuoka; G Rotman; A Ogawa; Y Shiloh; K Tamai; S J Elledge
Journal:  Proc Natl Acad Sci U S A       Date:  2000-09-12       Impact factor: 11.205

7.  Surveillance of herpes simplex virus resistance to antivirals: a 4-year survey.

Authors:  Sonia Burrel; Catherine Aime; Laurence Hermet; Zaïna Ait-Arkoub; Henri Agut; David Boutolleau
Journal:  Antiviral Res       Date:  2013-09-25       Impact factor: 5.970

8.  The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites.

Authors:  S Y Shieh; J Ahn; K Tamai; Y Taya; C Prives
Journal:  Genes Dev       Date:  2000-02-01       Impact factor: 11.361

9.  Chk2 is a tumor suppressor that regulates apoptosis in both an ataxia telangiectasia mutated (ATM)-dependent and an ATM-independent manner.

Authors:  Atsushi Hirao; Alison Cheung; Gordon Duncan; Pierre-Marie Girard; Andrew J Elia; Andrew Wakeham; Hitoshi Okada; Talin Sarkissian; Jorge A Wong; Takashi Sakai; Elisa De Stanchina; Robert G Bristow; Toshio Suda; Scott W Lowe; Penny A Jeggo; Stephen J Elledge; Tak W Mak
Journal:  Mol Cell Biol       Date:  2002-09       Impact factor: 4.272

10.  CD8(+) T cells can block herpes simplex virus type 1 (HSV-1) reactivation from latency in sensory neurons.

Authors:  T Liu; K M Khanna; X Chen; D J Fink; R L Hendricks
Journal:  J Exp Med       Date:  2000-05-01       Impact factor: 14.307

View more
  5 in total

1.  Phosphoproteomic Profiling Reveals Epstein-Barr Virus Protein Kinase Integration of DNA Damage Response and Mitotic Signaling.

Authors:  Renfeng Li; Gangling Liao; Raja Sekhar Nirujogi; Sneha M Pinto; Patrick G Shaw; Tai-Chung Huang; Jun Wan; Jiang Qian; Harsha Gowda; Xinyan Wu; Dong-Wen Lv; Kun Zhang; Srikanth S Manda; Akhilesh Pandey; S Diane Hayward
Journal:  PLoS Pathog       Date:  2015-12-29       Impact factor: 6.823

Review 2.  Targeting Host Cellular Factors as a Strategy of Therapeutic Intervention for Herpesvirus Infections.

Authors:  Kumari Asha; Neelam Sharma-Walia
Journal:  Front Cell Infect Microbiol       Date:  2021-03-19       Impact factor: 5.293

Review 3.  New Paradigms for the Study of Ocular Alphaherpesvirus Infections: Insights into the Use of Non-Traditional Host Model Systems.

Authors:  Matthew R Pennington; Eric C Ledbetter; Gerlinde R Van de Walle
Journal:  Viruses       Date:  2017-11-18       Impact factor: 5.048

4.  Human Kinase/Phosphatase-Wide RNAi Screening Identified Checkpoint Kinase 2 as a Cellular Factor Facilitating Japanese Encephalitis Virus Infection.

Authors:  Yi-Lin Chan; Ching-Len Liao; Yi-Ling Lin
Journal:  Front Cell Infect Microbiol       Date:  2018-05-17       Impact factor: 5.293

5.  HSV-1 Hijacks the Host DNA Damage Response in Corneal Epithelial Cells through ICP4-Mediated Activation of ATM.

Authors:  Oleg Alekseev; William E Donegan; Kelly R Donovan; Vladimir Limonnik; Jane Azizkhan-Clifford
Journal:  Invest Ophthalmol Vis Sci       Date:  2020-06-03       Impact factor: 4.799

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.